Dec 8 (Reuters) - Recursion Pharma (RXRX.O), opens new tab, which uses artificial intelligence to discover new drug candidates, said on Monday its experimental oral drug helped reduce abnormal growths ...
In early December 2025, Recursion Pharmaceuticals released clinical data from the TUPELO Phase 1b/2 trial of REC-4881, providing fresh insight into the candidate’s safety and efficacy profile. This ...
Wondering if Recursion Pharmaceuticals at around $4.83 is a beaten down bargain or a value trap? This breakdown walks through what the current market price is really implying. The stock has bounced ...
Recursion Pharmaceuticals, Inc. remains a Sell as pipeline progress, notably REC-4881 in FAP, fails to surpass cheap alternatives like Celebrex. REC-4881's Phase 1/2 data show a median polyp reduction ...
Google today released its 2025 Year in Search list, but don’t mistake it for a ranking of the “top searches” or the “most searched” terms. This year’s recap focused on trending queries – the topics ...
After twelve years at the helm of AI-drug developer Recursion, Chris Gibson will hand the CEO baton to Najat Khan, PhD, the company’s chief R&D officer and chief commercial officer, effective January ...
Zohran Mamdani, Erika Kirk and "KPop Demon Hunters" were among the top trending searches of 2025, Google's Year in Search has revealed. Charlie Kirk, 31, who was assassinated while speaking with ...
If you're looking for web links only in Google Search results, create a custom search shortcut for your browser. Peter is a writer and editor for the CNET How-To team. He has been covering technology, ...
Generative AI is infiltrating everything you do online, including how you find information. If you're bored with traditional search, check out the top AI search engines we've tried. I’ve been writing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback